ALTEOGEN Inc. (196170.KQ) KOE
Currency In KRW
- General
- Statistics
- Historical Data
- Profile
- Financials
ALTEOGEN Inc.
Address
62, Yuseong-daero
Daejeon, 34054
Korea (the Republic of)
Phone
82 4 2384 8780
Website
Sector
Healthcare
Industry
Biotechnology
Employees
145
First IPO Date
December 12, 2014
Key Executives
| Name | Title | Pay | Year Born |
| Soon-Jae Park | Chief Executive Officer | 0 | 1954 |
| Hang Yeon Kim | Chief Financial Officer & Executive Vice President | 0 | 1965 |
| Kyuwan Kim | Senior Vice President & Head of New Drug Development | 0 | N/A |
| Sang Woo Kang | Senior Vice President of Management Support Group | 0 | N/A |
| Vivek Shenoy | Chief Business Development Officer | 0 | N/A |
| Tae-Yon Chun | Executive Vice President & Corporate Alliance Officer | 0 | 1965 |
Description
ALTEOGEN Inc., a biotechnology firm, specializes in advancing long-acting biobetters, its own antibody-drug conjugates (ADCs), and antibody biosimilars. The company is actively progressing ALT-P1, a long-acting human growth hormone currently undergoing Phase IIa clinical evaluation, and ALT-Q2, a long-acting active form of coagulation factor VII designed for hemophilia treatment, leveraging its proprietary NexP platform. Additionally, ALTEOGEN is further advancing ALT-P7, a precision oncology treatment for breast and gastric cancers presently in Phase I clinical trials, and ALT-Q5, an ADC targeting ovarian cancer, utilizing its NexMab ADC platform. The company also engages in strategic collaborations, including one with Kissei Pharmaceutical for the advancement of Aflibercept, which has successfully concluded preclinical testing. Another partnership is with Cristalia for Trastuzumab, currently in Phase II clinical trials for breast cancer treatment. Established in 2008, ALTEOGEN Inc. maintains its headquarters in Daejeon, South Korea.
